Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Peptides & Oligos Logo (drop shadow)

PART OF NEXTGEN BIOMED 2027

18 - 19 March 2027 | InterContinental London - The O2, London, UK

Programme Summary

Delve into cutting-edge innovations in peptides and oligonucleotides discovery, therapeutics development & optimisation with key opinion leaders addressing novel computational tools, analytical strategies and sustainable chemistry & manufacturing practices.

Hear Peter Franko, Portfolio Director, introduce the programme

DAY TWO

Peptides & Oligonucleotides Keynote Address

Fernando Albericio, Professor, University of KwaZulu-Natal

Fernando Albericio is a Research Professor at the University of KwaZulu-Natal (South Africa) and Emeritus Professor of Organic Chemistry at the University of Barcelona (Spain) with 50 years of experience in peptide chemistry.
His major research interests cover practically all aspects of peptide synthetic methodology as well as the synthesis of peptides and small molecules with therapeutic activities (cancer and infectious diseases). Lastly, he was working on greening the solid-phase peptide synthesis processes. He has published more than 1000 scientific articles, filed more than 60 patents, and graduated more than 80 Ph.D. students.

2027 Highlights

Peptides

Spotlight what’s next in peptide therapeutics - cutting-edge chemistry, AI/ML-driven
analysis, peptide display and sequencing, with case studies spanning oncology,
regenerative medicine, and beyond.

Oligonucleotides

Stay ahead in oligonucleotide discovery & optimisation - hear from GSK, Sixfold Bio,
Roche, Novo Nordisk and others on computational tools, novel mechanisms, delivery
breakthroughs, and clinical progress. 

NextGen Biomed - What to Expect Exhibiting 3
NextGen Biomed - What to Expect Networking 1
1000

leading pharma, biotech, regulatory & academic delegates

700
pre-arranged 1-2-1 meetings, facilitating business growth
50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including fireside chats & refreshments
NGB + LSX Combined Logo-1

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things NextGen Biomed, direct to your inbox.

NGB Newsletter Icon-1

Peptides & Oligonucleotides Agenda at a Glance

DAY ONE TRACKS

Track 6: Peptide Discovery & Green Chemistry
Track 7: Oligonucleotide Discovery & Green Chemistry

DAY TWO TRACKS

Track 5: Peptide Therapeutics &  Development
Track 6: Oligonucleotide Therapeutic Development &
Optimisation  

NGB 2026 Laptop Agenda

Featured Speakers for Peptides & Oligonucleotides 2027

Carolina Säll
Principal Scientist,
Novo Nordisk
Ekaterina Grinko
Business Innovation & Partnerships Lead Obesity/GLP-1,
Novo Nordisk
Hanne Nielsen
Director, Center for Biopharmaceuticals and Biobarriers in Drug Delivery,
University of Copenhagen
Hilmar Warenius
CEO and Co-founder,
Syntherix Ltd
Kai Hilpert
Professor,
St George’s University of London
Knud Jørgen Jensen
Professor,
Copenhagen University
Mark Frigerio
VP, Head of Platform Technology & Science,
Bicycle Therapeutics plc
Michael Davies
Chief Executive Officer,
Carocell Bio
Olga Obrezanova
AI Principal Scientist,
AstraZeneca
Origène Nyanguile
Professor,
HES-SO Valais-Wallis

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Register Now

Be part of the new wave of Biomed R&D innovation

Partner with us

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients